Clinical Trial Update: Calcium and Vitamin D to Optimize Bone Mass in Boys With Risperidone-induced Hyperprolactinemia [Phase 3]

View source ↗

Summary

Phase 3 trial investigating calcium and vitamin D to optimize bone mass in boys with risperidone-induced hyperprolactinemia has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bone Mass Reduction Related to Antipsychotic Use
• Risperidone-induced Hyperprolactinemia

Snippet

Sponsor: Chadi A. Calarge | Conditions: Risperidone-induced Hyperprolactinemia | Phase 3 | Status: COMPLETED | Results posted: 2017-12-26